The CML patient’s subgroup that harbored high CD34+CD38- SCs burden either before the start of therapy or at a major molecular response showed shorter OS; and shorter PFS. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.